Cancer Drug ADI-PEG 20 Ready for Phase III Trial
Written by WTJ on October 20, 2008 – 5:02 pm -
ADI-PEG 20 is a cancer drug that is developed by TDW Pharmaceuticals. TDW Pharmaceuticals is the Taiwanese subsidiary of the US-based Polaris Group of pharmaceutical companies. ADI-PEG 20 is a cancer drug for liver and cancer and metastatic melanoma, which is safer than Sorafenib. It is ready for Phase III clinical trials to test on large patient groups. The drug is promising for pancreatic, prostrate and kidney cancers treatment. Unlike conventional cancer drugs which destroy cancer cells’ DNA, ADI-PEG 20 is a protein drug that breaks down arginine (required by cancer cells to grow and survive) in human blood, hence inhibit the proliferation and growth of cancer. Another advantage of ADI-PEG 20 is that it only need to be injected once a week and won’t affect the survival of normal cells. The drug is expected to release into market at the end of 2011.
Related posts:
Tags: ADI-PEG 20, arginine, cancer, cancer drug, cancer treatment, drug, Polaris Group, Sorafenib, taiwan, TDW Pharmaceuticals, Wu Bor-wen | No Comments »
